8 January 2024
Emerging treatment approaches such as peptides demonstrate marked improvements for people with type-2 diabetes or obesity. However, their poor oral bioavailability requires subcutaneous injections, leading to a high ecological burden due to single-use devices and frequent injections. This has prompted a focus on optimizing drug delivery devices for these medicines. Emerging approaches leverage bio-based materials or reusable devices, but the resulting net sustainability effect is often only incremental. Other emerging technologies, such as jet injectors or oral delivery devices still face usability and safety concerns.
Boehringer Ingelheim is dedicated to environmental preservation and seeks collaborations for innovative drug delivery concepts that go far beyond current solutions. As part of our latest opnMe call, we invite you as an expert to propose concepts that have a potential for a breakthrough in the challenging field of more sustainable drug delivery with a time horizon to reach the market within the next 5 – 10 years.
How would you propose to overcome technological, conceptual, and economic hurdles associated with the development of a next generation drug delivery device with a more favorable ecological footprint?
By participating, you have a unique chance to push the boundaries and make a significant impact in the field of drug delivery devices. You will benefit by collaborating directly with the cross-functional experts of the Device Development team of Boehringer Ingelheim.
We foresee that eligible solutions may come from scientists with very different backgrounds, ranging from academia, start-up’s, biotech, or even larger enterprises such as device or pharmaceutical companies.
As a winner, you can expect sufficient monetary funding to progress your conceptual ideas towards clinical readiness. Increasing complexity and maturity of the proposed solution will require different budget terms that will be negotiated with the selected partners in good faith. Beyond funding we offer support in engineering capabilities for design reviews, including a strong connection to patient insights, prototyping or pharmacokinetics studies with a range of relevant molecules.
Apply soon as your proposals can only be accepted if they arrive by March 6, 2024, 11:59 pm PST.
No registration required
Subscribe to our newsletter to stay updated as we add new molecules or calls to opnMe.com.
About our opn2EXPERTS question:
How would you propose to overcome technological, conceptual, and economic hurdles associated with the development of a next generation drug delivery device with a more favorable ecological footprint? With ambitious questions such as this, we share precisely formulated technological questions with the expert community on opnMe. We welcome game-changing ideas from academia, startups, biotech, and larger corporations. Winners receive custom benefit packages. Particular emphasis will be made on finding mutually agreeable solutions concerning each partner’s rights & obligations (including intellectual property rights).
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, our ‘Molecules to order’ are provided to the scientific community for free to help unlock and fulfill their full potential. For ‘Molecules for Collaboration’, such as our RIPK2 inhibitor, you have a chance to receive funding by submitting a testable research proposal that shows a role of RIPK2 in novel disease indications with high unmet medical need. As part of our third pillar, our ‘opn2EXPERTS’ program, we enlist scientific advice on key biologic and technological issues to fuel further drug discovery and development to address unmet patient needs. An example is the recent call on ‘high-concentration liquid formulations of biologics’. To pursue their professional career, PostDoc’s have the chance to pursue to join Boehringer Ingelheim as part of the opn2TALENTS program.